Clinical trials unit

Parexel Appoints Gwyn Bebb, BM, BCh., Ph.D., to Lead Oncology Clinical Development

Retrieved on: 
Tuesday, September 19, 2023
Amgen, BM, Clinical trials unit, POET, Drug development, University, Tom Baker Cancer Centre, Head, Cancer, Research, Department of Medicine – University of Pamplona, Lung, Natural science, Patient, ChromeOS, Nursing, Medical imaging, Parexel

In this role Dr. Bebb will lead the research and development of new cancer treatments for biopharmaceutical customers worldwide.

Key Points: 
  • In this role Dr. Bebb will lead the research and development of new cancer treatments for biopharmaceutical customers worldwide.
  • “The complexities of oncology require agile, multifaceted teams to push the boundaries of drug development and deliver groundbreaking treatment options for patients with cancer,” said Amy McKee, M.D., Chief Medical Officer and Head, Oncology Center of Excellence.
  • Most recently he was a Clinical Research Medical Director at Amgen in both early- and late-stage oncology drug development where he shepherded a biphasic T cell engager to a confirmational Phase III trial.
  • His experience also includes clinical practice as a Medical Oncologist focused on lung and gastrointestinal cancers.

SEC Charges Terraform and CEO Do Kwon with Defrauding Investors in Crypto Schemes

Retrieved on: 
Thursday, February 16, 2023
Crypto, District court, Cryptocurrency, Clinical trials unit, LUNA, Complaint, Security (finance), PTE, UST, Joint Sigint Cyber Unit, Terraform, Complex, Douglas v. U.S. District Court ex rel Talk America, Terra

According to the SEC’s complaint, from April 2018 until the scheme’s collapse in May 2022, Terraform and Kwon raised billions of dollars from investors by offering and selling an inter-connected suite of crypto asset securities, many in unregistered transactions.

Key Points: 
  • According to the SEC’s complaint, from April 2018 until the scheme’s collapse in May 2022, Terraform and Kwon raised billions of dollars from investors by offering and selling an inter-connected suite of crypto asset securities, many in unregistered transactions.
  • The complaint further alleges that Terraform and Kwon offered and sold investors other means to invest in their crypto empire, including the crypto asset security tokens MIR—or “mirror” tokens—and LUNA itself.
  • The SEC’s complaint alleges that Terraform and Kwon marketed crypto asset securities to investors seeking to earn a profit, repeatedly claiming that the tokens would increase in value.
  • Meanwhile, Terraform and Kwon also allegedly misled investors about the stability of UST.

Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

Retrieved on: 
Tuesday, November 22, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Clinical trial, CTU, Brain, Survival, University, Centre de documentation de la musique contemporaine, European Medicines Agency, Infarction, STEMI, University Hospitals Birmingham NHS Foundation Trust, Stroke, A&B, BHP, Blood, Medicine, ISIN, Queen Elizabeth Hospital, Degenerative disease, Partnership, Myocardial infarction, ESOC, Mortality, Intracerebral hemorrhage, Clinical trials unit, MI, University of Birmingham, EMA, Document, Angioplasty, Queen Elizabeth Hospital Birmingham (1933–2010), Thrombosis, GPVI, Therapy, Mab, Hospital, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Northern General Hospital, VI, Associate, Heart, Patient, Medical device, Pharmaceutical industry, INSERM, Cardiology

Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.

Key Points: 
  • Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.
  • A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK.
  • Although immediate opening of the blocked coronary artery by angioplasty in cases of heart attack is now routine, significant heart damage still occurs.
  • Were delighted to work with Acticor to see whether this new class of drug has the potential to improve the outcomes of our patients with heart attacks.

Boeing to Pay $200 Million to Settle SEC Charges that it Misled Investors about the 737 MAX

Retrieved on: 
Thursday, September 22, 2022
Clinical trials unit, Safety, Gaps, Maneuvering Characteristics Augmentation System, Human, Department, Crash, Sarbanes, MAX, Sarbanes–Oxley Act, State bureau of investigation, Grief, Maintenance, Lion Air Flight 610, Government, United States Department of Justice Criminal Division, Certification, Fair Fund, U.S. Securities and Exchange Commission, CEO, Ethiopian Airlines, Security (finance), Flight 302, SEC, MCAS, Federal Bureau of Investigation, South Carolina Law Enforcement Division, Airline, Muilenburg, Boeing

The crashes involved Boeings 737 MAX airplane and a flight control function called the Maneuvering Characteristics Augmentation System (MCAS).

Key Points: 
  • The crashes involved Boeings 737 MAX airplane and a flight control function called the Maneuvering Characteristics Augmentation System (MCAS).
  • "There are no words to describe the tragic loss of life brought about by these two airplane crashes," said SEC Chair Gary Gensler.
  • They misled investors by providing assurances about the safety of the 737 MAX, despite knowing about serious safety concerns.
  • that somehow slipped through [the] certification process for the 737 MAX and that Boeing had gone back and confirmed again .

SEC Charges VMware with Misleading Investors by Obscuring Financial Performance

Retrieved on: 
Monday, September 12, 2022
Securities Act of 1933, U.S. Securities and Exchange Commission, Associate, VMware, Clinical trials unit, Security (finance), Division, Disclosure

According to the SECs order, VMware shifted tens of millions of dollars in revenue into future quarters, building a buffer in those periods and obscuring the companys financial performance as its business slowed relative to projections in fiscal year 2020.

Key Points: 
  • According to the SECs order, VMware shifted tens of millions of dollars in revenue into future quarters, building a buffer in those periods and obscuring the companys financial performance as its business slowed relative to projections in fiscal year 2020.
  • "As the SECs order finds, by making misleading statements about order management practices, VMware deprived investors of important information about its financial performance," said Mark Cave, Associate Director in the Division of Enforcement.
  • The SECs order finds that VMware violated antifraud provisions of the Securities Act of 1933 as well as certain reporting provisions of the federal securities laws.
  • Without admitting or denying the findings in the SECs order, VMware consented to a cease-and-desist order and to pay an $8 million penalty.

SEC Charges Advisory Firm and Executives with Devising an Elaborate Scheme to Defraud Clients out of More Than $75 Million

Retrieved on: 
Tuesday, August 30, 2022
Security (finance), Complex, Division, U.S. Securities and Exchange Commission, District court, Investment Advisers Act of 1940, Chicago Region Environmental and Transportation Efficiency Program, SEC, Clinical trials unit, Investment, Douglas v. U.S. District Court ex rel Talk America, Fraud, Federal Accounting Standards Advisory Board, Financial adviser

According to the SECs complaint, from July 2017 through 2018, Lindberg and Herwig, through Standard Advisory, breached their fiduciary duties to their advisory clients by fraudulently causing them to engage in undisclosed related-party transactions that were not in the best interest of their clients.

Key Points: 
  • According to the SECs complaint, from July 2017 through 2018, Lindberg and Herwig, through Standard Advisory, breached their fiduciary duties to their advisory clients by fraudulently causing them to engage in undisclosed related-party transactions that were not in the best interest of their clients.
  • The SECs complaint further alleges that the defendants misappropriated more than $57 million in client funds and that Standard Advisory collected more than $21.4 million in advisory fees generated in connection with these schemes.
  • "Todays filing demonstrates that the SEC will take action to protect investors from investment advisers who attempt to evade fundamental fiduciary responsibilities."
  • The litigation will be led by Alyssa Qualls and Kevin Wisniewski of the Trial Unit.

UBS to Pay $25 Million to Settle SEC Fraud Charges Involving Complex Options Trading Strategy

Retrieved on: 
Wednesday, June 29, 2022
Clinical trials unit, Investment Advisers Act of 1940, U.S. Securities and Exchange Commission, Division, Sale, Sarbanes, YES, Risk, Investment, Complex, SEC, Time, UBS, Sarbanes–Oxley Act, Security (finance), Financial adviser

Washington, D.C.--(Newsfile Corp. - June 29, 2022) - The Securities and Exchange Commission today announced that UBS Financial Services Inc. has agreed to pay approximately $25 million to settle fraud charges relating to a complex investment strategy referred to as YES, or Yield Enhancement Strategy.

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - June 29, 2022) - The Securities and Exchange Commission today announced that UBS Financial Services Inc. has agreed to pay approximately $25 million to settle fraud charges relating to a complex investment strategy referred to as YES, or Yield Enhancement Strategy.
  • According to the SECs order, UBS marketed and sold YES to approximately 600 investors through its platform of domestic financial advisors from February 2016 through February 2017.
  • When investors suffered losses, many of them, along with their financial advisors, expressed surprise and closed their YES accounts.
  • Complex products can present unique risks, and the SEC will remain vigilant and continue to take action to protect those who invest in these products from misconduct.

Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

Retrieved on: 
Tuesday, June 7, 2022
Memory, IND, Coronavirus Scientific Advisory Board (Turkey), University of Arizona College of Medicine – Tucson, COVID-19, Dementia, Lists of diseases, Research, U.S. Securities and Exchange Commission, Barrow Neurological Institute, Brain, Forward-looking statement, Center, University of California, Davis, Center for Mind and Brain, Program, Securities Exchange Act of 1934, Securities Act of 1933, SAB, Communication, Cognition, Keck School of Medicine of USC, Mind, Neurodegeneration, Security (finance), Clinical trials unit, University, Patient, DRS, Athira Pharma, Electrophysiology, FAAN, Private Securities Litigation Reform Act, LinkedIn, Nature, UC, Investment, GLOBE, NASDAQ, Lewy body, Twitter, Banner, Instagram, Safety, Pharmaceutical industry, Neuroscience, Neurology, Psychiatry, Medicine, Facebook, L. Athira Krishna

BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a Scientific Advisory Board (SAB) comprised of renowned leaders in neurology and neurodegenerative disease research Drs.

Key Points: 
  • BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a Scientific Advisory Board (SAB) comprised of renowned leaders in neurology and neurodegenerative disease research Drs.
  • Our advisory board includes experts with extensive experience in neurology research and clinical investigations at prestigious national institutions.
  • Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

SEC Charges Global Steel Pipe Manufacturer with Violating Foreign Corrupt Practices Act

Retrieved on: 
Thursday, June 2, 2022
Private prosecution, Repubblica, Brazilian Federation of Associations of Librarians, Information Scientists and Institutions, Securities Exchange Act of 1934, Petrobras, Mercado, Security (finance), Environment, Record, SMV, Clinical trials unit, Foreign Corrupt Practices Act, Justice, Book, FCPA, SEC, Department, Securities and Exchange Commission (Philippines), United States Department of Justice Tax Division, Online gambling, Tenaris

Washington, D.C.--(Newsfile Corp. - June 2, 2022) - The Securities and Exchange Commission today announced that Tenaris, a Luxembourg-based global manufacturer and supplier of steel pipe products, will pay more than $78 million to resolve charges that it violated the Foreign Corrupt Practices Act (FCPA) in connection with a bribery scheme involving its Brazilian subsidiary.

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - June 2, 2022) - The Securities and Exchange Commission today announced that Tenaris, a Luxembourg-based global manufacturer and supplier of steel pipe products, will pay more than $78 million to resolve charges that it violated the Foreign Corrupt Practices Act (FCPA) in connection with a bribery scheme involving its Brazilian subsidiary.
  • "Tenaris failed for many years to implement sufficient internal accounting controls throughout its business operations despite known corruptions risks," said Charles Cain, Chief of the SEC Enforcement Divisions FCPA Unit.
  • "This failure created the environment in which bribes were facilitated through a constellation of companies associated with its controlling shareholder."
  • It was supervised by Tracy L. Price, Deputy Chief of the SEC Enforcement Divisions FCPA Unit.

SEC Charges RiverSource Distributors with Improper Switching of Variable Annuities

Retrieved on: 
Wednesday, May 25, 2022
Clinical trials unit, U.S. Securities and Exchange Commission, RiverSource, Investment Company Act of 1940, Section 11 of the Canadian Charter of Rights and Freedoms, Program, SEC, LLC, Complex, Security (finance), Financial adviser

Washington, D.C.--(Newsfile Corp. - May 25, 2022) - The Securities and Exchange Commission today announced settled charges against RiverSource Distributors Inc. for improper switching or replacing of variable annuities.

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - May 25, 2022) - The Securities and Exchange Commission today announced settled charges against RiverSource Distributors Inc. for improper switching or replacing of variable annuities.
  • This is the SECs first-ever enforcement proceeding under Section 11 of the Investment Company Act of 1940.
  • According to the SECs order, RiverSource offered and sold variable annuities to retail investors through an affiliated broker-dealer/investment adviser, Ameriprise Financial Services, LLC.
  • The order finds that certain employees of RiverSource developed and implemented a sales practice that caused exchange offers to be made to holders of variable annuities to switch from one variable annuity to another which had the effect of increasing sales commissions for RiverSource employees, while also increasing RiverSources variable annuity related revenues.